Max has seven years’ experience working in pricing and market access consultancy, with a focus on rare diseases and oncology. Through his work at both the specific product and wider portfolio level, he has extensive experience in partnering with clients to ensure all recommendations translate into clear and actionable strategies.
Max holds an MRes in Molecular and Cellular Biosciences from Imperial College London.
Since joining Dolon in 2023, Max has been supporting the (T)epkinly project team across both DLBCL and FL workstreams.
